138 related articles for article (PubMed ID: 28571116)
1. Plasma microRNA signature is associated with risk stratification in prostate cancer patients.
Al-Qatati A; Akrong C; Stevic I; Pantel K; Awe J; Saranchuk J; Drachenberg D; Mai S; Schwarzenbach H
Int J Cancer; 2017 Sep; 141(6):1231-1239. PubMed ID: 28571116
[TBL] [Abstract][Full Text] [Related]
2. Circulating microRNAs in plasma before and after radical prostatectomy.
McDonald AC; Raman JD; Shen J; Liao J; Pandya B; Vira MA
Urol Oncol; 2019 Nov; 37(11):814.e1-814.e7. PubMed ID: 31421994
[TBL] [Abstract][Full Text] [Related]
3. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.
Pashaei E; Pashaei E; Ahmady M; Ozen M; Aydin N
PLoS One; 2017; 12(6):e0179543. PubMed ID: 28651018
[TBL] [Abstract][Full Text] [Related]
5. Increased levels of serum miR-148a-3p are associated with prostate cancer.
Dybos SA; Flatberg A; Halgunset J; Viset T; Rolfseng T; Kvam S; Skogseth H
APMIS; 2018 Sep; 126(9):722-731. PubMed ID: 30160020
[TBL] [Abstract][Full Text] [Related]
6. Expression profile analysis of microRNAs in prostate cancer by next-generation sequencing.
Song C; Chen H; Wang T; Zhang W; Ru G; Lang J
Prostate; 2015 Apr; 75(5):500-16. PubMed ID: 25597612
[TBL] [Abstract][Full Text] [Related]
7. The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease.
Kurul NO; Ates F; Yilmaz I; Narli G; Yesildal C; Senkul T
Prostate; 2019 Jul; 79(10):1125-1132. PubMed ID: 31045265
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
9. Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy.
Zedan AH; Hansen TF; Assenholt J; Madsen JS; Osther PJS
Prostate; 2019 Mar; 79(4):425-432. PubMed ID: 30537232
[TBL] [Abstract][Full Text] [Related]
10. Circulating microRNA signature for the diagnosis of very high-risk prostate cancer.
Alhasan AH; Scott AW; Wu JJ; Feng G; Meeks JJ; Thaxton CS; Mirkin CA
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10655-60. PubMed ID: 27601638
[TBL] [Abstract][Full Text] [Related]
11. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort.
Mihelich BL; Maranville JC; Nolley R; Peehl DM; Nonn L
PLoS One; 2015; 10(4):e0124245. PubMed ID: 25874774
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer.
Katz B; Reis ST; Viana NI; Morais DR; Moura CM; Dip N; Silva IA; Iscaife A; Srougi M; Leite KR
PLoS One; 2014; 9(11):e113700. PubMed ID: 25409297
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA alteration and putative target genes in high-grade prostatic intraepithelial neoplasia and prostate cancer: STAT3 and ZEB1 are upregulated during prostate carcinogenesis.
Cha YJ; Lee JH; Han HH; Kim BG; Kang S; Choi YD; Cho NH
Prostate; 2016 Jul; 76(10):937-47. PubMed ID: 27017949
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN.
Zhou K; Zhang T; Fan Y; Serick ; Du G; Wu P; Geng D
Tumour Biol; 2016 Oct; 37(10):13469-13477. PubMed ID: 27465551
[TBL] [Abstract][Full Text] [Related]
17. A circulating miRNA assay as a first-line test for prostate cancer screening.
Sharova E; Grassi A; Marcer A; Ruggero K; Pinto F; Bassi P; Zanovello P; Zattoni F; D'Agostino DM; Iafrate M; Ciminale V
Br J Cancer; 2016 Jun; 114(12):1362-6. PubMed ID: 27228285
[TBL] [Abstract][Full Text] [Related]
18. Expression of microRNAs associated with Gleason grading system in prostate cancer: miR-182-5p is a useful marker for high grade prostate cancer.
Tsuchiyama K; Ito H; Taga M; Naganuma S; Oshinoya Y; Nagano K; Yokoyama O; Itoh H
Prostate; 2013 Jun; 73(8):827-34. PubMed ID: 23184537
[TBL] [Abstract][Full Text] [Related]
19. The utility of urine-circulating miRNAs for detection of prostate cancer.
Stuopelyte K; Daniunaite K; Bakavicius A; Lazutka JR; Jankevicius F; Jarmalaite S
Br J Cancer; 2016 Sep; 115(6):707-15. PubMed ID: 27490805
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of miRNA host gene promoter methylation in prostate cancer.
Daniunaite K; Dubikaityte M; Gibas P; Bakavicius A; Rimantas Lazutka J; Ulys A; Jankevicius F; Jarmalaite S
Hum Mol Genet; 2017 Jul; 26(13):2451-2461. PubMed ID: 28398479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
